## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application: <u>Listing of Claims</u>:

- (Currently Amended) A method for alleviating a condition associated with
  prostate cancer selected from the group consisting of prostatic enlargement, urinary
  incontinence, urinary retention, and urge-type dysfunction, the method comprising the step of
  injecting a therapeutically effective amount of botulinum toxin type A into the prostate gland of
  a patient with prostate cancer, thereby alleviating said condition associated with prostate cancer.
  - (Cancelled)
  - (Cancelled)
- 4. (Previously Presented) The method of claim 1, wherein the condition associated with prostate cancer is urinary incontinence.
- (Previously Presented) The method according to claim 1, where the patient is a human.
  - 6-19. (Cancelled)
- 20. (Previously Presented) The method of claim 1, wherein the condition is prostatic enlargement.
  - (Cancelled)
- 22. (Previously Presented) The method of claim 1, wherein the therapeutically effective amount of botulinum toxin type A is up to 2500 units.
- 23. (Previously Presented) The method of Claim 1, wherein the therapeutically effective amount of botulinum toxin type A is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A.
- 24. (Previously Presented) The method of Claim 1, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.